NIVOLUMAB (Opdivo) prior authorization at Molina Healthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Molina Healthcare requires Programmed Death Receptor-1 Blocking Antibody prior-authorization documentation for NIVOLUMAB (Opdivo): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Molina Healthcare reviews NIVOLUMAB (Opdivo) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody. Molina Healthcare-specific context: Primary Medicaid MCO + ACA Marketplace in 21 states. 42 CFR Part 438 Subpart F applies. State Fair Hearing is the escalation path after internal MCO appeal.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Molina Healthcare's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Medicaid MCO carve-outs
- Step therapy
- Specialty pharmacy denials
NIVOLUMAB (Opdivo)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Off-label indication denial despite NCCN compendium support
- Combination with ipilimumab denied as duplicate therapy
- Adjuvant use denial citing 'no overall survival data'
- Continuation beyond 2 years
Brand: Opdivo. PD-1 inhibitor approved across 20+ indications. Opdualag (nivolumab + relatlimab) is the first LAG-3 combination. Subcutaneous nivolumab (Opdivo Qvantig) FDA-approved December 2024 — appeal denials of subQ formulation citing IV-only preference.
Manufacturer patient-assistance program: BMS Access Support — relevant when a Molina Healthcare denial sticks and the patient needs bridge access while appealing.
How Molina Healthcare approaches Immune checkpoint inhibitors PAs
For NIVOLUMAB (OPDIVO), check whether the current Molina Healthcare Immune checkpoint inhibitors policy cites specialty pharmacy denials. Pharmacy-benefit review for NIVOLUMAB (OPDIVO) at Molina Healthcare is routed through state-specific Medicaid carve-in PBMs (varies by state Medicaid contract). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Molina Healthcare; if denied, use the filing date and route printed on that denial notice. Off-label oncology appeals at Molina Healthcare carry significantly higher reversal rates when the appeal letter cites the specific NCCN compendium evidence-block category (2A or above) rather than peer-reviewed citations alone. Molina Healthcare is domiciled in CA, so unresolved appeals escalate to the CA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.molinahealthcare.com/providers) with the same packet plus an applicable, current clinical source supporting NIVOLUMAB (Opdivo)for the patient's indication.
Medicare Advantage cases may have plan reconsideration and independent-review steps. Confirm the current level, forwarding rule, and any expedited pathway directly in the notice before selecting an escalation route.
Molina Healthcare Medicare Advantage organization determinations operate under 42 CFR Part 422 Subpart D. For NIVOLUMAB (OPDIVO), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. The applicable decision period and any Independent Review Entity routing depend on the request type, current rule, and plan notice. Record the cited source and version, then verify the operational due date against the current notice and CMS materials before relying on it.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Molina Healthcare denial on DenialHelp.
Contact Molina Healthcare
- Provider portal: https://www.molinahealthcare.com/providers
Frequently asked questions
What documentation does Molina Healthcare need for NIVOLUMAB (Opdivo) prior auth?
Molina Healthcare's typical PA packet for NIVOLUMAB (Opdivo): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Molina Healthcare?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for NIVOLUMAB (Opdivo) at Molina Healthcare?
Preparation scenarios to check against the current notice and policy include: Medicaid MCO carve-outs; Step therapy; Specialty pharmacy denials. These are not measured frequency claims. For NIVOLUMAB (Opdivo), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does Molina Healthcare cover off-label use of NIVOLUMAB (OPDIVO) supported by NCCN compendium?
Molina Healthcare may consult the NCCN Drugs & Biologics Compendium for oncology coverage. For off-label NIVOLUMAB (OPDIVO), cite the current compendium entry by version and table, name the evidence-block category, and attach the supporting clinical-trial or meta-analysis reference. Verify the member-specific coverage rule and timing before relying on this preparation guide. Pharmacy-benefit handling is routed through state-specific Medicaid carve-in PBMs (varies by state Medicaid contract). External-review escalation for Molina Healthcare fully-insured policies sits with the CA insurance department.
How do I prep for a peer-to-peer with Molina Healthcare on NIVOLUMAB (Opdivo)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the NIVOLUMAB (Opdivo) PA packet
Open ApprovalHelp — generate a NIVOLUMAB (Opdivo) prior-auth packet tailored to Molina Healthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com